Apyx Medical Corp (NASDAQ:APYX) Expected to Post Earnings of -$0.16 Per Share
Equities research analysts expect Apyx Medical Corp (NASDAQ:APYX) to post ($0.16) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Apyx Medical’s earnings, with estimates ranging from ($0.19) to ($0.13). Apyx Medical reported earnings per share of ($0.10) in the same quarter last year, which would indicate a negative year-over-year growth rate of 60%. The firm is expected to report its next quarterly earnings results on Wednesday, March 11th.
On average, analysts expect that Apyx Medical will report full year earnings of ($0.59) per share for the current year. For the next financial year, analysts anticipate that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.78) to ($0.55). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Apyx Medical.
Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. Apyx Medical had a negative net margin of 66.77% and a negative return on equity of 20.25%. The company had revenue of $7.58 million during the quarter, compared to analysts’ expectations of $6.78 million. The business’s quarterly revenue was up 106.3% on a year-over-year basis.
NASDAQ:APYX traded down $0.11 during trading hours on Monday, hitting $8.17. The stock had a trading volume of 947 shares, compared to its average volume of 80,240. The company has a 50 day simple moving average of $8.09 and a two-hundred day simple moving average of $7.26. The firm has a market capitalization of $280.52 million, a price-to-earnings ratio of -15.72 and a beta of 0.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.73 and a quick ratio of 7.93. Apyx Medical has a one year low of $3.55 and a one year high of $8.89.
Institutional investors have recently bought and sold shares of the company. Calamos Advisors LLC bought a new stake in shares of Apyx Medical during the 4th quarter worth $1,164,000. Astoria Strategic Wealth Inc. purchased a new position in shares of Apyx Medical in the 4th quarter worth about $86,000. Metropolitan Life Insurance Co NY purchased a new position in shares of Apyx Medical in the 3rd quarter worth about $87,000. State Street Corp increased its position in shares of Apyx Medical by 34.2% during the 3rd quarter. State Street Corp now owns 557,677 shares of the company’s stock valued at $3,775,000 after purchasing an additional 142,098 shares during the last quarter. Finally, Frisch Financial Group Inc. increased its position in shares of Apyx Medical by 31.7% during the 3rd quarter. Frisch Financial Group Inc. now owns 17,658 shares of the company’s stock valued at $120,000 after purchasing an additional 4,248 shares during the last quarter. Hedge funds and other institutional investors own 52.45% of the company’s stock.
Apyx Medical Company Profile
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
Featured Story: What is required to own or exchange cryptocurrency?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.